Efficacy of combination therapy in non-insulin dependent diabetes mellitus
- 17 Downloads
Secondary failure of oral hypoglycaemic agents raises the dilemma of whether to institute therapy with insulin alone, or in combination. We reviewed our experience of combination therapy following secondary failure of oral hypoglycaemic therapy. Seventeen subjects were receiving combination therapy for 6 months or more. Such treatment was associated with a significant fall in HbA1C — from 10.7±0.38 per cent to 8.3±0.35 per cent (p<0.01) after 6 months and remained significantly reduced at 12 months (8.7±0.34 per cent (p<0.01)). Mean body weight, systolic and diastolic blood pressure were unchanged during treatment with adjuvant insulin therapy. Insulin therapy is a useful adjunct in the daily management of subjects with NIDDM who experience secondary failure of oral hypoglycaemic agents.
KeywordsMetformin Insulin Therapy Glycaemic Control Acarbose Gliclazide
- 1.Riflkin, H. (Ed): The Physician’s Guide to Type II Diabetes (NIDDM): Diagnosis and Treatment. New York, American Diabetes Association 1984: 21–52.Google Scholar
- 4.Lebovitz, H. E. Oral Hypoglycaemic Agents. In: The Diabetes Annual Vol. 3. Alberti, K. G. M. M., Krall, L. P., Eds. New York, Elsevier, 1987:72–93.Google Scholar
- 8.Barnett, A. H., Bowen Jones, D., Burden, A. C., Janes, J. M., Sinclair, A., Small, M., Tindall, H. Multicentre study to assess quality of life and glycaemic control of Type 2 diabetic patients treated with insulin compared with oral hypoglycamic agents. Practical Diabetes International 1996; 13: 179–183.CrossRefGoogle Scholar
- 15.Lee, J. S., Lu, M., Lee, V. S., Russell, D., Bahr, C., Lee, E. T. Lower-extremity amputation: incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study. Diabetes Care 1993; 42: 876–882.Google Scholar